Advancing Relief: Highlights from 'Dry Eye Innovations & Keeping Up with Dry Eye Treatment Updates in 2025
More than 2,600 eye care professionals attended our two most recent continuing education events, highlighting the growing interest in cutting-edge dry eye management.
On our recent CE events, eye care professionals gathered for an in-depth continuing education course focused on the latest advances in diagnosing and treating dry eye disease. The session covered a range of modern strategies for managing ocular surface disease, emphasizing real-world case examples that demonstrated how a multimodal, targeted approach can address the complex nature of dry eye. Attendees explored emerging therapies including pharmacologic agents, amniotic membranes, intense pulsed light (IPL), radiofrequency, photobiomodulation, and meibomian gland expression technologies—gaining valuable insights into how to combine these tools for synergistic, patient-specific results.
Our recent continuing education (CE) event, led by Dr. Jessilyn Quint, was attended by over 1,200 eye care professionals, highlighting the growing interest in modern dry eye management.
She started by defining exactly what dry eye is and went through some updates from the DEWS III study, including the new questionnaires and treatment algorithms.
She then discussed neurostimulation, current and new pharmacological treatments, as well as BBL, IPL, and LLT. She also talked about thermal expression, muscle stimulation, microblepharoexfoliation, eyelid irrigation, autologous serum, PRP drops, amniotic membranes, and nutraceuticals.
She finished by talking about what is coming down the pipeline in dry eye diagnosis and treatments.
Our continuing education (CE) event with Dr. Mila Ioussifova drew over 1,400 eye care professionals, all eager to deepen their understanding of today’s dry eye treatment landscape.
Dr. Ioussifova began by reviewing the signs and symptoms of dry eye, along with various questionnaires, treatment algorithms, and key studies used to guide diagnosis and care. She emphasized the importance of tear osmolarity and ocular surface health, including how to interpret normal vs. abnormal patient results.
The lecture then moved into meibomian gland dysfunction (MGD) treatments, covering:
Thermal heating procedures
Radiofrequency
Photobiomodulation
Intense pulsed light (IPL)
Low-level light therapy (LLLT)
Dr. Ioussifova also addressed related conditions such as ocular rosacea and Demodex, and reviewed emerging treatments including dynamic muscle stimulation (DMSt), neurostimulation, and the role of micronutrients in ocular surface disease.
